ProjectIMMUNED - CA209-184
Basic data
Title:
IMMUNED - CA209-184
Duration:
01/04/2015 to 30/06/2021
Abstract / short description:
A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of Disease - IMMUNED
Keywords:
immunotherapy
Immuntherapie
Nivolumab
Ipilimumab
melanoma
Melanom
skin cancer
Hautkrebs
Involved staff
Managers
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Contact persons
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
Duisburg, Nordrhein-Westfalen, Germany